NIKKEI 225
38,442.77 -394.69 (-1.02%) HANG SENG
18,505.56 +61.45 (+0.33%) CRUDE OIL
73.18 -0.07 (-0.10%) GOLD FUTURES
2,356.70 +9.30 (+0.40%) DOW
38,711.29 +140.26 (+0.36%) Bitcoin GBP
55,699.62 +1,558.95 (+2.88%)
Soleno Therapeutics Inc (6XC.DU)
| Previous close | 38.50 |
| Open | 38.38 |
| Bid | 37.30 x N/A |
| Ask | 38.16 x N/A |
| Day's range | 37.38 - 38.38 |
| 52-week range | 34.10 - 48.04 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireSoleno Therapeutics Set to Join Russell 3000® Index
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24
- GlobeNewswire
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4,
- GlobeNewswire
Soleno Therapeutics to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare ConferenceDay: Wednesday, June 5, 2024Time:11:30 AM Eastern Time Event:Goldman Sachs 45th Annual Global Healthcare
